FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053452179> ?p ?o ?g. }

• W2053452179 endingPage "384" @default.
• W2053452179 startingPage "381" @default.
• W2053452179 abstract "Uncontrolled study has demonstrated the usefulness of somatostatin in the tratment of mild Graves' ophthalmopathy (GO). We performed a prospective study to evaluate the usefulness of somatostatin as compared to corticosteroid in the treatment of moderately severe GO. All patients were rendered euthyroid and observed for 3 months to exclude spontaneous improvement without active treatment. They were randomized to receive either somatostatin (SS, octreotide 200 μh q8h subcutaneously, n = 8) or corticosteroid (CS, prednisone 1 mg/kg/day in decreasing doses, n = 10). Assessments of soft tissue inflammation, exophthalmos, palpebral aperture, intraocular pressure, diplopia, cornea, and visual acuity were made every 4 weeks for 3 months. MRI of the orbit was performed before and after treatment. Both SS and CS therapy decreased the palpebrai aperture and activity score after 3 months (p < 0.05), but those treated with CS had a lower activity score after treatment when compared to SS [2.5 (1-7) v.s. 3.5 (0-4), median (range), p < 0.05]. Only CS, but not SS, was able to reduce intraocular pressure and muscle size as documented by MRI, but no significant reduction in proptosis was observed in either group. Also, patients' self-assessments of the eye changes after treatment were similar between the two groups. Both groups showed significant elevation of urinary glycosaminoglycan (GAG) excretion before therapy (SS 24.6 ± 10.8; CS 27.8 ± 11.4 mg/24 h), which was reduced after treatment (SS 12.5 ± 7.3; CS 10.8 ± 6.3 mg/24 h, p < 0.05). However, no significant correlation could be observed between the degree of GAG reduction and the clinical outcome of the patients. In conclusion, the long acting SS octreotide was effective in reducing soft tissue inflammation and providing symptomatic relief in GO but not as effective as corticosteroid in reducing muscle size. In view of the minimal side-effects and similar efficacy as compared to corticosteroid in patients with minimal extraocular muscle enlargement, it is suggested that a trial of SS may be considered in selected patients with GO." @default.
• W2053452179 created "2016-06-24" @default.
• W2053452179 creator A5004996923 @default.
• W2053452179 creator A5045530547 @default.
• W2053452179 creator A5069468828 @default.
• W2053452179 creator A5082482005 @default.
• W2053452179 date "1996-10-01" @default.
• W2053452179 modified "2023-10-02" @default.
• W2053452179 title "The Effect of Somatostatin versus Corticosteroid in the Treatment of Graves' Ophthalmopathy" @default.
• W2053452179 cites W1663514770 @default.
• W2053452179 cites W1965113827 @default.
• W2053452179 cites W1966754802 @default.
• W2053452179 cites W1971240351 @default.
• W2053452179 cites W2004978312 @default.
• W2053452179 cites W2006611896 @default.
• W2053452179 cites W2014105565 @default.
• W2053452179 cites W2042945613 @default.
• W2053452179 cites W2048051957 @default.
• W2053452179 cites W2051745084 @default.
• W2053452179 cites W2054564647 @default.
• W2053452179 cites W2071522931 @default.
• W2053452179 cites W2075556135 @default.
• W2053452179 cites W2163387976 @default.
• W2053452179 cites W2334870842 @default.
• W2053452179 cites W2397438050 @default.
• W2053452179 cites W2616562178 @default.
• W2053452179 cites W4376598022 @default.
• W2053452179 doi "https://doi.org/10.1089/thy.1996.6.381" @default.
• W2053452179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8936659" @default.
• W2053452179 hasPublicationYear "1996" @default.
• W2053452179 type Work @default.
• W2053452179 sameAs 2053452179 @default.
• W2053452179 citedByCount "85" @default.
• W2053452179 countsByYear W20534521792013 @default.
• W2053452179 countsByYear W20534521792014 @default.
• W2053452179 countsByYear W20534521792015 @default.
• W2053452179 countsByYear W20534521792016 @default.
• W2053452179 countsByYear W20534521792017 @default.
• W2053452179 countsByYear W20534521792018 @default.
• W2053452179 countsByYear W20534521792019 @default.
• W2053452179 countsByYear W20534521792020 @default.
• W2053452179 crossrefType "journal-article" @default.
• W2053452179 hasAuthorship W2053452179A5004996923 @default.
• W2053452179 hasAuthorship W2053452179A5045530547 @default.
• W2053452179 hasAuthorship W2053452179A5069468828 @default.
• W2053452179 hasAuthorship W2053452179A5082482005 @default.
• W2053452179 hasConcept C126322002 @default.
• W2053452179 hasConcept C126894567 @default.
• W2053452179 hasConcept C134018914 @default.
• W2053452179 hasConcept C141071460 @default.
• W2053452179 hasConcept C2776297358 @default.
• W2053452179 hasConcept C2776804153 @default.
• W2053452179 hasConcept C2777195454 @default.
• W2053452179 hasConcept C2777433750 @default.
• W2053452179 hasConcept C2778257484 @default.
• W2053452179 hasConcept C2778720950 @default.
• W2053452179 hasConcept C2779609023 @default.
• W2053452179 hasConcept C2781025020 @default.
• W2053452179 hasConcept C2781092963 @default.
• W2053452179 hasConcept C2984496839 @default.
• W2053452179 hasConcept C526584372 @default.
• W2053452179 hasConcept C71315377 @default.
• W2053452179 hasConcept C71924100 @default.
• W2053452179 hasConcept C90924648 @default.
• W2053452179 hasConceptScore W2053452179C126322002 @default.
• W2053452179 hasConceptScore W2053452179C126894567 @default.
• W2053452179 hasConceptScore W2053452179C134018914 @default.
• W2053452179 hasConceptScore W2053452179C141071460 @default.
• W2053452179 hasConceptScore W2053452179C2776297358 @default.
• W2053452179 hasConceptScore W2053452179C2776804153 @default.
• W2053452179 hasConceptScore W2053452179C2777195454 @default.
• W2053452179 hasConceptScore W2053452179C2777433750 @default.
• W2053452179 hasConceptScore W2053452179C2778257484 @default.
• W2053452179 hasConceptScore W2053452179C2778720950 @default.
• W2053452179 hasConceptScore W2053452179C2779609023 @default.
• W2053452179 hasConceptScore W2053452179C2781025020 @default.
• W2053452179 hasConceptScore W2053452179C2781092963 @default.
• W2053452179 hasConceptScore W2053452179C2984496839 @default.
• W2053452179 hasConceptScore W2053452179C526584372 @default.
• W2053452179 hasConceptScore W2053452179C71315377 @default.
• W2053452179 hasConceptScore W2053452179C71924100 @default.
• W2053452179 hasConceptScore W2053452179C90924648 @default.
• W2053452179 hasIssue "5" @default.
• W2053452179 hasLocation W20534521791 @default.
• W2053452179 hasLocation W20534521792 @default.
• W2053452179 hasOpenAccess W2053452179 @default.
• W2053452179 hasPrimaryLocation W20534521791 @default.
• W2053452179 hasRelatedWork W1548669396 @default.
• W2053452179 hasRelatedWork W1982345662 @default.
• W2053452179 hasRelatedWork W2001118094 @default.
• W2053452179 hasRelatedWork W2013777072 @default.
• W2053452179 hasRelatedWork W2039766818 @default.
• W2053452179 hasRelatedWork W2131979641 @default.
• W2053452179 hasRelatedWork W2151397963 @default.
• W2053452179 hasRelatedWork W2166429238 @default.
• W2053452179 hasRelatedWork W2335272111 @default.
• W2053452179 hasRelatedWork W2417887763 @default.
• W2053452179 hasVolume "6" @default.

• next